Skip to main content

Incannex Healthcare Inc.

corporate_fare Company Profile

Incannex Healthcare Inc.

IXHL·NASDAQ·Life Sciences·CIK 0001873875

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious chronic conditions. The company's primary development focus is IHL-42X for obstructive sleep apnea (OSA). They are also evaluating the next clinical development plan for PSX-001 in generalized anxiety disorder (GAD) and the potential for further development of IHL-675A in inflammatory conditions. The goal is to provide additional treatment options for patients whose needs are not adequately met by existing care. IHL-42X, the lead drug candidate for OSA, is an oral fixed-dose combination of dronabinol and acetazolamide. This combination is designed to work synergistically by targeting two different physiological pathways linked to the intermittent hypoxia and hypercapnia characteristic of OSA. The company completed the Phase 2 portion of its RePOSA Phase 2/3 clinical trial in July 2025, which showed that IHL-42X reduced apnea hypopnea index (AHI), improved patient-reported outcomes, and was well-tolerated in OSA patients. In December 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for IHL-42X for OSA treatment. Incannex Healthcare Inc. is conducting an additional dose confirmation study, the DReAMzz Study, to optimize the ratio of dronabinol and acetazolamide before advancing to a Phase 3 clinical trial for IHL-42X. The DReAMzz Study is a Phase 2 dose confirmation crossover trial evaluating nine dose combinations of IHL-42X across approximately 120 subjects at 14 U.S. clinical sites. This study started in May 2026, began screening participants in July 2026, is currently enrolling participants, and is estimated to be completed in mid-2027. Results from the DReAMzz Study are expected to inform the design of a planned Phase 3 clinical trial for IHL-42X. PSX-001, another lead drug candidate in clinical development after completing a Phase 2 trial, is an oral synthetic psilocybin treatment administered with psychological therapy for patients with moderate-to-severe GAD.

Incannex Healthcare Inc. (NASDAQ:IXHL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for IXHL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for IXHL spans 10-Q, 10-K, 8-K.

Recent high-impact activity:

  • Incannex Quarterly Loss Blows Past Estimates as Revenue Stays at Zero
  • Incannex Q1 Loss Narrows to $1.9M; Material Weakness Persists
  • Incannex 10-K: Going Concern Removed, $67.7M Cash, But Material Weakness Persists
  • Incannex Doses First Patient in DReAMzz Phase 2 Study of IHL-42X
  • Final A$5.1M R&D Tax Refund Lands, Completing A$11.2M in Non-Dilutive Capital for 2026

Financial Snapshot

Fiscal year ended June 30, 2026
Revenue
$0
Net Income
-$19.3M
Diluted EPS
-$1.66
Op. Cash Flow
-$12.87M
Free Cash Flow
-$12.88M
Operating Income
-$23.03M
Cash & Equivalents
$67.71M
Debt / Equity
0.00×
Shares Outstanding
12.54M sh
Source: 10-K · filed 2026-09-25 · accession 0001628280-26-063506

Short Interest & Short Volume

5.70 days to cover

FINRA reported short interest of 358,009 shares in IXHL as of the October 30, 2026 settlement, a 13.0% decrease from the prior period — about 5.7 days to cover at its recent average daily volume. On November 20, 2026, 22.5% of IXHL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)358,009 shares as of October 30, 2026
Change vs prior period▼ 13.0%
Days to cover5.70 at avg daily volume of 62,849
Daily short volume (FINRA facilities)22.5% of 103,642 shares on November 20, 2026
5-day average short volume24.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$1.91 +2.60% today
52-week range · as of 2026-11-12 $1.91 – $14.91
Market cap
$23.34M
Volume
220.7K (2.2× avg)
3-mo avg 101.2K
Live data · 2026-11-22 01:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IXHL - Latest Insights

IXHL
Nov 12, 2026, 11:52 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.01
Real-time Price: $1.91 info
Change: -$0.1017 (-5%) info
Market Cap: $23.336M info
IXHL
Nov 12, 2026, 8:29 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.98
Real-time Price: $1.91 info
Change: -$0.0717 (-4%) info
Market Cap: $23.336M info
IXHL
Sep 25, 2026, 8:41 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.40
Real-time Price: $1.91 info
Change: -$1.49 (-44%) info
Market Cap: $23.336M info
IXHL
Aug 25, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.33
Real-time Price: $1.91 info
Change: -$1.42 (-43%) info
Market Cap: $23.336M info
IXHL
Aug 11, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.33
Real-time Price: $1.91 info
Change: -$1.42 (-43%) info
Market Cap: $23.336M info
IXHL
Jul 23, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.06
Real-time Price: $1.91 info
Change: -$1.15 (-38%) info
Market Cap: $23.336M info
IXHL
Jun 25, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.54
Real-time Price: $1.91 info
Change: -$1.63 (-46%) info
Market Cap: $23.336M info
IXHL
Jun 25, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $1.91 info
Change: -$1.30 (-40%) info
Market Cap: $23.336M info
IXHL
Jun 10, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.76
Real-time Price: $1.91 info
Change: -$1.85 (-49%) info
Market Cap: $23.336M info
IXHL
Jun 10, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.59
Real-time Price: $1.91 info
Change: -$1.68 (-47%) info
Market Cap: $23.336M info
IXHL
Jun 09, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.30
Real-time Price: $1.91 info
Change: -$1.39 (-42%) info
Market Cap: $23.336M info
IXHL
May 15, 2026, 9:29 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.88
Real-time Price: $1.91 info
Change: -$1.97 (-51%) info
Market Cap: $23.336M info
IXHL
May 14, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.78
Real-time Price: $1.91 info
Change: -$1.87 (-50%) info
Market Cap: $23.336M info
IXHL
May 12, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.41
Real-time Price: $1.91 info
Change: -$2.50 (-57%) info
Market Cap: $23.336M info
IXHL
Apr 22, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $3.88
Real-time Price: $1.91 info
Change: -$1.97 (-51%) info
Market Cap: $23.336M info
IXHL
Apr 22, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.88
Real-time Price: $1.91 info
Change: -$1.97 (-51%) info
Market Cap: $23.336M info
IXHL
Mar 27, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.36
Real-time Price: $1.91 info
Change: -$1.45 (-43%) info
Market Cap: $23.336M info
IXHL
Mar 25, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.85
Real-time Price: $1.91 info
Change: -$0.9417 (-33%) info
Market Cap: $23.336M info
IXHL
Mar 18, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.31
Real-time Price: $1.91 info
Change: -$1.40 (-42%) info
Market Cap: $23.336M info
IXHL
Mar 17, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.22
Real-time Price: $1.91 info
Change: -$1.31 (-41%) info
Market Cap: $23.336M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets